BR112015001106A2 - processo para produzir compostos de isoquinolina - Google Patents

processo para produzir compostos de isoquinolina

Info

Publication number
BR112015001106A2
BR112015001106A2 BR112015001106A BR112015001106A BR112015001106A2 BR 112015001106 A2 BR112015001106 A2 BR 112015001106A2 BR 112015001106 A BR112015001106 A BR 112015001106A BR 112015001106 A BR112015001106 A BR 112015001106A BR 112015001106 A2 BR112015001106 A2 BR 112015001106A2
Authority
BR
Brazil
Prior art keywords
compounds
isoquinoline compounds
hypha
activity
producing isoquinoline
Prior art date
Application number
BR112015001106A
Other languages
English (en)
Other versions
BR112015001106B1 (pt
Inventor
Min Park Jung
D Thompson Michael
P Arend Michael
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of BR112015001106A2 publication Critical patent/BR112015001106A2/pt
Publication of BR112015001106B1 publication Critical patent/BR112015001106B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epidemiology (AREA)

Abstract

resumo processo para produzir compostos de isoquinolina a presente invenção refere-se a métodos para a preparação de compostos de isoquinolina e os compostos intermediários obtidos assim. tais compostos podem ser utilizados para preparar os compostos e composições capazes de diminuir a atividade da enzima hidroxilase hif, aumentando assim a estabilidade e / ou atividade do fator indutível hipoxia (hif).
BR112015001106-3A 2012-07-16 2013-07-15 Métodos para a produção de compostos de isoquinolina BR112015001106B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261672191P 2012-07-16 2012-07-16
US61/672,191 2012-07-16
PCT/US2013/050538 WO2014014834A1 (en) 2012-07-16 2013-07-15 Process for making isoquinoline compounds

Publications (2)

Publication Number Publication Date
BR112015001106A2 true BR112015001106A2 (pt) 2017-06-27
BR112015001106B1 BR112015001106B1 (pt) 2021-11-09

Family

ID=48857024

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015001106-3A BR112015001106B1 (pt) 2012-07-16 2013-07-15 Métodos para a produção de compostos de isoquinolina

Country Status (22)

Country Link
US (2) US9340511B2 (pt)
EP (2) EP3219706A1 (pt)
JP (1) JP6196671B2 (pt)
KR (1) KR102145272B1 (pt)
CN (2) CN106083719B (pt)
AU (1) AU2013290437B2 (pt)
BR (1) BR112015001106B1 (pt)
CA (1) CA2879238C (pt)
CY (1) CY2022018I2 (pt)
DK (1) DK2872487T3 (pt)
ES (1) ES2631655T3 (pt)
HU (2) HUE034409T2 (pt)
IL (1) IL236625B (pt)
IN (1) IN2015KN00265A (pt)
MX (1) MX350922B (pt)
MY (1) MY171483A (pt)
NZ (1) NZ704660A (pt)
PL (1) PL2872487T3 (pt)
PT (1) PT2872487T (pt)
SG (1) SG11201500234YA (pt)
WO (1) WO2014014834A1 (pt)
ZA (1) ZA201500664B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1644336E (pt) 2003-06-06 2011-04-21 Fibrogen Inc Compostos de heteroarilo que contêm azoto e sua utilização no aumento da eritropoetina endógena
AU2009314155B2 (en) 2008-11-14 2015-10-08 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
MY171483A (en) 2012-07-16 2019-10-15 Fibrogen Inc Process for making isoquinoline compounds
ES2905898T3 (es) * 2012-07-16 2022-04-12 Fibrogen Inc Formas cristalinas de un inhibidor de prolil hidroxilasa
KR102291860B1 (ko) 2013-06-06 2021-08-20 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형
CN103694172A (zh) * 2013-12-26 2014-04-02 辽宁亿灵科创生物医药科技有限公司 含氮杂芳基化合物的衍生物
AU2015311333B2 (en) 2014-09-02 2017-11-16 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
WO2016045125A1 (en) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
CN104447547B (zh) * 2014-11-10 2017-04-19 苏州康润医药有限公司 4‑氨基异喹啉‑8‑甲酸甲酯的合成方法
CN106146490B (zh) * 2015-03-27 2018-10-23 沈阳三生制药有限责任公司 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途
CN104892509B (zh) * 2015-06-04 2018-03-09 苏州明锐医药科技有限公司 诺得司他的制备方法
CN106187888A (zh) * 2016-07-18 2016-12-07 江苏德源药业股份有限公司 Fg‑4592单晶及其制备方法
CN106478503A (zh) * 2016-09-29 2017-03-08 上海勋和医药科技有限公司 Roxadustat中间体的制备方法
CZ2016627A3 (cs) 2016-10-07 2018-04-18 Zentiva, K.S. Způsob přípravy (7-fenoxy-4-hydroxy-1-methylisochinolin-3-karbonyl)glycinu (roxadustatu) a jeho intermediátů založený na souběžném otevírání oxazolového kruhu, štěpení etheru a tvorbě iminu
CN107954931B (zh) * 2016-10-17 2021-06-22 上海医药集团青岛国风药业股份有限公司 一种诺得司他的制备方法
WO2018140186A1 (en) 2017-01-28 2018-08-02 Kingchem Life Science Llc A process for preparing 5-phenoxy-1(3h)isobenzofuranone
WO2019106621A1 (en) * 2017-12-01 2019-06-06 Dr. Reddy's Laboratories Limited Process for the preparation of roxadustat and its intermediates
CN109956870A (zh) * 2017-12-14 2019-07-02 南京卡文迪许生物工程技术有限公司 一种罗沙司他的合成方法及其中间体化合物
CN110218184B (zh) * 2018-03-01 2022-09-27 广东东阳光药业有限公司 诺德司他共晶及其制备方法
WO2019174631A1 (zh) * 2018-03-16 2019-09-19 上海医药集团股份有限公司 一种诺得司他的制备方法
CN110526813B (zh) * 2018-05-24 2022-06-28 杭州科巢生物科技有限公司 异喹啉化合物的制备方法及其中间体
CN111978225B (zh) 2018-06-05 2022-03-04 沈阳化工大学 一种三氟乙基硫醚（亚砜）取代苯类化合物及其用途
CN113302175A (zh) 2018-11-09 2021-08-24 维瓦斯治疗公司 双环化合物
CN109776415B (zh) * 2019-03-07 2020-11-17 福建南方制药股份有限公司 一种Roxadustat中间体的制备方法
CN114072207B (zh) 2019-04-16 2024-03-29 维瓦斯治疗公司 双环化合物
RU2709493C1 (ru) * 2019-08-01 2019-12-18 Марат Феликсович Фазылов Способ получения роксадустата
US20220340532A1 (en) * 2019-08-07 2022-10-27 Teva Pharmaceuticals International Gmbh Processes for the preparation of roxadustat and intermediates thereof
CN112441975B (zh) * 2019-09-03 2023-10-31 西藏嘉信景天药业有限公司 一种罗沙司他重要中间体的制备方法
WO2021073623A1 (zh) * 2019-10-18 2021-04-22 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
CN112679430B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
CN112679431B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
CN113444042A (zh) * 2020-03-27 2021-09-28 南京海润医药有限公司 一种罗沙司他的制备方法
WO2021214785A1 (en) * 2020-04-21 2021-10-28 Mylan Laboratories Limited Improved process for the preparation of roxadustat
CN111533691A (zh) * 2020-06-08 2020-08-14 重庆三圣实业股份有限公司 一种罗沙司他的制备方法
CN113801060A (zh) 2020-06-13 2021-12-17 苏州鹏旭医药科技有限公司 一种多取代异喹啉化合物的制备方法
JP7368636B2 (ja) * 2020-06-19 2023-10-24 ジャンプカン（シャンハイ）メディカル テクノロジー カンパニー リミテッド ロキサデュスタット及びその中間体の合成方法とその中間体
CN112409258A (zh) * 2020-11-20 2021-02-26 杭州科巢生物科技有限公司 一种罗沙司他的制备方法
CN114644589A (zh) * 2020-12-17 2022-06-21 鲁南制药集团股份有限公司 一种化合物n-[（4-羟基--1-甲基-3-异喹啉基）羰基]-甘氨酸的制备方法
US20230101768A1 (en) * 2021-08-13 2023-03-30 The Board Of Regents Of The University Of Texas System Method to treat manganese toxicity and manganese-induced parkinsonism in humans
CN115124467A (zh) * 2022-07-11 2022-09-30 天津力生制药股份有限公司 一种罗沙司他关键中间体的制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036964A (en) 1973-10-11 1977-07-19 Beecham Group Limited Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en) 1973-10-30 1976-11-02 Sandoz, Inc. 3-Substituted-4-aryl isoquinolines
DE2818423A1 (de) 1978-04-27 1979-11-08 Hoechst Ag Neue isochinolinderivate und verfahren zu ihrer herstellung
DE3233424A1 (de) 1982-09-09 1984-03-15 Hoechst Ag, 6230 Frankfurt Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4558006A (en) 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US4559403A (en) 1983-05-19 1985-12-17 Hoffmann-La Roche Inc. Substituted isoquinolines
US4584379A (en) 1985-01-22 1986-04-22 Merrell Dow Pharmaceuticals Inc. Isoquinoline thromboxane synthetase inhibitors
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4822800A (en) 1986-06-09 1989-04-18 Ortho Pharmaceutical Corporation Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4952588A (en) 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
US4966906A (en) 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
DE59401924D1 (de) 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
EP0650960B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
WO1996018616A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
DE69736812T2 (de) 1996-11-27 2007-08-09 Bristol-Myers Squibb Pharma Co. Neue integrin rezeptor antagonisten
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US20040146964A1 (en) 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
GB0107901D0 (en) * 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
AU2002312371A1 (en) 2001-06-13 2002-12-23 Roland W. Burli Aryl-benzimidazole compounds having antiinfective activity
EP1401817A4 (en) 2001-06-13 2005-11-02 Genesoft Pharmaceuticals Inc ISOQUINOLINE COMPOUNDS WITH ANTI-INFECTIOUS ACTIVITY
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
CN100522946C (zh) 2001-12-06 2009-08-05 法布罗根股份有限公司 低氧诱导因子(HIF)α的稳定化
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
PT1644336E (pt) * 2003-06-06 2011-04-21 Fibrogen Inc Compostos de heteroarilo que contêm azoto e sua utilização no aumento da eritropoetina endógena
EP1646611A1 (en) 2003-07-15 2006-04-19 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
WO2005011696A1 (en) 2003-08-01 2005-02-10 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
AU2004263508A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
CA2567619A1 (en) 2004-05-28 2005-12-15 Fibrogen, Inc. Hif prolyl hydroxylase activity assay
AP2007004047A0 (en) * 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
WO2006094292A2 (en) 2005-03-02 2006-09-08 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
EP1893186A2 (en) 2005-06-06 2008-03-05 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
WO2006138511A2 (en) 2005-06-15 2006-12-28 Fibrogen, Inc. Use of hif 1alfa modulators for treatment of cancer
US7801864B2 (en) * 2005-11-28 2010-09-21 Commvault Systems, Inc. Systems and methods for using metadata to enhance data identification operations
JP5161793B2 (ja) 2006-01-27 2013-03-13 フィブロジェン， インコーポレイテッド 低酸素症誘導因子（ｈｉｆ）を安定化するシアノイソキノリン化合物
JP2009528279A (ja) 2006-02-16 2009-08-06 ファイブローゲン、インコーポレーテッド 脳卒中を治療するための化合物および方法
CN103497184A (zh) 2006-04-04 2014-01-08 菲布罗根有限公司 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
EP2227475B1 (en) 2007-12-03 2014-02-19 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
WO2010022240A1 (en) 2008-08-20 2010-02-25 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
AU2009314155B2 (en) 2008-11-14 2015-10-08 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
US20140171465A1 (en) 2011-01-13 2014-06-19 Fibrogen, Inc. Methods For Increasing Reticulocyte Hemoglobin Content
WO2012106472A1 (en) 2011-02-02 2012-08-09 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase
KR102029951B1 (ko) * 2011-07-22 2019-11-08 베이징 베타 파머수티컬 컴퍼니 리미티드 프로릴 히드록실라제 억제제로서 화합물의 다형체형, 및 이의 용도
CN104470899B (zh) 2012-03-09 2017-12-26 菲布罗根有限公司 作为hif羟化酶抑制剂的4‑羟基‑异喹啉化合物
ES2905898T3 (es) 2012-07-16 2022-04-12 Fibrogen Inc Formas cristalinas de un inhibidor de prolil hidroxilasa
MY171483A (en) 2012-07-16 2019-10-15 Fibrogen Inc Process for making isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
RU2666144C2 (ru) 2013-01-24 2018-09-06 Фиброген, Инк. Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты
KR102291860B1 (ko) 2013-06-06 2021-08-20 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형

Also Published As

Publication number Publication date
CN106083719A (zh) 2016-11-09
US20150175550A1 (en) 2015-06-25
MX350922B (es) 2017-09-25
JP2015524409A (ja) 2015-08-24
HUE034409T2 (en) 2018-02-28
MY171483A (en) 2019-10-15
IN2015KN00265A (pt) 2015-06-12
SG11201500234YA (en) 2015-02-27
BR112015001106B1 (pt) 2021-11-09
CY2022018I1 (el) 2023-01-05
DK2872487T3 (en) 2017-06-06
CA2879238C (en) 2021-08-10
AU2013290437B2 (en) 2017-11-02
IL236625B (en) 2019-01-31
KR20150058147A (ko) 2015-05-28
CY2022018I2 (el) 2023-01-05
NZ704660A (en) 2017-10-27
EP3219706A1 (en) 2017-09-20
EP2872487B1 (en) 2017-04-26
US9340511B2 (en) 2016-05-17
IL236625A0 (en) 2015-02-26
ES2631655T3 (es) 2017-09-01
HUS2200030I1 (hu) 2022-07-28
WO2014014834A1 (en) 2014-01-23
CA2879238A1 (en) 2014-01-23
EP2872487A1 (en) 2015-05-20
KR102145272B1 (ko) 2020-08-18
CN103435546B (zh) 2016-08-10
AU2013290437A1 (en) 2015-02-19
CN106083719B (zh) 2019-10-18
JP6196671B2 (ja) 2017-09-13
US20160194285A1 (en) 2016-07-07
PL2872487T3 (pl) 2017-09-29
ZA201500664B (en) 2017-08-30
CN103435546A (zh) 2013-12-11
PT2872487T (pt) 2017-05-15
MX2015000505A (es) 2015-07-17
US9708269B2 (en) 2017-07-18

Similar Documents

Publication Publication Date Title
BR112015001106A2 (pt) processo para produzir compostos de isoquinolina
WO2014028429A3 (en) Enzymes and polymerases for the synthesis of rna
WO2013151668A3 (en) Modified polynucleotides for the production of secreted proteins
BR112017028322A2 (pt) compostos, processo para a produção de compostos i, para a produção de compostos ii dos compostos iii e para a produção de compostos iii, compostos intermediários v e utilização dos compostos i
EA201592074A1 (ru) Композиции и способы изменения сигнальной системы вторичного мессенджера
WO2014100779A8 (en) Methods for production of platelets from pluripotent stem cells and compositions thereof
BR112012020693A8 (pt) Derivados de ciclobutano e metilciclobutano como inibidores de janus quinase e composição que os compreende
MX342287B (es) Moduladores heterociclicos de sintesis lipidica.
BR112012027509A2 (pt) composto, processo para a preparação de composto, composição farmacêutica, uso de composto, e, método
BR112013018515A2 (pt) derivados de pirrol tricíclico, processo para preparação e seu uso como inibidores da quinase
TR201902476T4 (tr) Kaplamalı Substratların Üretim Süreci
BR112013023517A2 (pt) "inibidores de produção de leucotrieno, seus usos, e composição farmacêutica"
MY195343A (en) A Novel Phtalazinone Derivatives and Manufacturing Process Thereof
NZ730334A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
MX347882B (es) Procedimiento mejorado para preparar (3e, 7e)-homofarnesol.
BR112017009545A2 (pt) composição antibacteriana, método para a preparação de uma composição, bacteriófago, ácido nucleico isolado, polipeptídeo isolado, e uso de um bacteriófago, ácido nucleico ou polipeptídeo
BR112017010010A2 (pt) método para produzir 3-oxo-5-hidroxipentanoil-coa, método para biossintetizar 1,3-butanodiol, hospedeiro recombinante, produto bioderivado, produto biobaseado ou produto derivado de fermentação, retícula bioquímica de ocorrência não natural, construto de ácido nucleico ou vetor de expressão e composição
BR112013016863A2 (pt) processo para produzir um polistereterol
BR112016009062A2 (pt) Composição antibacteriana, método para a preparação de uma composição, método para prever ou determinar a eficácia de uma terapia de bacteriófago em um indivíduo, método para selecionar um indivíduo ou determinar se um indivíduo é susceptível de se beneficiar de uma terapia com bacteriófagos, bacteriófago, ácido nucleico isolado, e, polipeptídeo isolado
BR112017004214A2 (pt) processo para a preparação de pigmentos de hematita, e processo para a preparação de pigmentos vermelhos de óxido de ferro
FI20115328A0 (fi) Uusia kutinaaseja, niiden tuottaminen ja käytöt
EA201691006A1 (ru) Морфологические формы гексадецилоксипропиловых сложных эфиров фосфоновой кислоты и способы их синтеза
WO2017029553A3 (en) Methods, cells and reagents for production of isoprene, derivatives and intermediates thereof
BR112015007830A2 (pt) aumento do rendimento para plantas suscetíveis ao estresse
BR112017011275A2 (pt) composição, e, processo para a produção de xarope de glicose.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 217/26

Ipc: C07D 217/26 (2006.01), A61P 39/00 (2006.01), A61P

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/07/2013, OBSERVADAS AS CONDICOES LEGAIS.